Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective increased by Piper Sandler from $6.00 to $7.00 in a research report report published on Monday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

ADPT has been the subject of a number of other reports. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. BTIG Research increased their price target on Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd.

Adaptive Biotechnologies Trading Down 1.3 %

Adaptive Biotechnologies stock opened at $5.85 on Monday. The stock has a 50 day moving average of $4.91 and a 200-day moving average of $4.22. The stock has a market cap of $863.34 million, a P/E ratio of -4.37 and a beta of 1.45. Adaptive Biotechnologies has a 52 week low of $2.28 and a 52 week high of $6.70.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. JTC Employer Solutions Trustee Ltd purchased a new stake in Adaptive Biotechnologies in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new stake in Adaptive Biotechnologies in the third quarter worth $34,000. Rothschild Investment LLC acquired a new position in shares of Adaptive Biotechnologies during the 2nd quarter valued at about $36,000. MQS Management LLC bought a new position in shares of Adaptive Biotechnologies in the second quarter valued at approximately $36,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in Adaptive Biotechnologies during the 1st quarter worth $46,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.